A Newcastle biotech company is set to lose more than $6 million a year in cuts to research and development tax incentives proposed by the Albanese government.
ImmVirX, which has a research and development arm in Newcastle, runs clinical trials of immunotherapy for patients with colorectal and ovarian cancer.